CSTL stock forecast
Our latest prediction for Castle Biosciences Inc's stock price was made on the Nov. 28, 2022 when the stock price was at 20.61$.
In the short term (2weeks), CSTL's stock price should underperform the market by -2.37%. During that period the price should oscillate between -8.13% and +4.41%.
In the medium term (3months), CSTL's stock price should underperform the market by -4.96%. During that period the price should oscillate between -27.65% and +25.71%.Get email alerts
Create a solid portfolio with CSTL
About Castle Biosciences Inc
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq), cutaneous squamous cell carcinoma (DecisionDx®-SCC), suspicious pigmented lesions (DecisionDx® DiffDx™-Melanoma) and uveal melanoma (DecisionDx®-UM, DecisionDx®-PRAME and DecisionDx®-UMSeq).Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -2.04$ per share.
The book value per share is 4.82$
Three months stock forecastNov. 28, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|